Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy

Despite guideline recommendations, access to hepatitis C virus (HCV) treatment is frequently restricted, with some payers approving therapy for only those with advanced disease or cirrhosis. However, delaying potentially curative treatment until the development of advanced liver disease may have cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Reau, Nancy, Vekeman, Francis, Wu, Eric, Bao, Yanjun, Gonzalez, Yuri Sanchez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721412/
https://www.ncbi.nlm.nih.gov/pubmed/29404471
http://dx.doi.org/10.1002/hep4.1049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721412/
https://www.ncbi.nlm.nih.gov/pubmed/29404471
http://dx.doi.org/10.1002/hep4.1049

Ejemplares similares